Revance Therapeutics (RVNC) PT Raised to $51.00

Revance Therapeutics (NASDAQ:RVNC) had its price objective upped by equities research analysts at Piper Jaffray Companies from $28.00 to $51.00 in a research report issued on Tuesday. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price target indicates a potential upside of 51.56% from the stock’s previous close.

A number of other equities analysts have also recently issued reports on RVNC. BidaskClub cut shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. Zacks Investment Research cut shares of Revance Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 12th. Cantor Fitzgerald set a $50.00 price objective on shares of Revance Therapeutics and gave the company a “buy” rating in a research note on Tuesday. ValuEngine cut shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday. Finally, JMP Securities assumed coverage on shares of Revance Therapeutics in a research note on Tuesday, August 22nd. They issued an “outperform” rating and a $34.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $40.75.

Revance Therapeutics (NASDAQ:RVNC) opened at $33.65 on Tuesday. Revance Therapeutics has a one year low of $15.85 and a one year high of $37.20.

Revance Therapeutics (NASDAQ:RVNC) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.95) by ($0.06). Revance Therapeutics had a negative net margin of 37,161.00% and a negative return on equity of 67.85%. The company had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.05 million. During the same quarter in the previous year, the company earned ($0.64) earnings per share. Revance Therapeutics’s revenue for the quarter was up .0% compared to the same quarter last year. equities analysts forecast that Revance Therapeutics will post -3.73 earnings per share for the current year.

In related news, CEO L Daniel Browne sold 7,600 shares of the stock in a transaction dated Wednesday, September 20th. The shares were sold at an average price of $23.58, for a total transaction of $179,208.00. Following the completion of the sale, the chief executive officer now owns 148,450 shares in the company, valued at approximately $3,500,451. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mark J. Foley bought 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 7th. The shares were purchased at an average price of $26.96 per share, with a total value of $539,200.00. Following the transaction, the director now directly owns 6,000 shares in the company, valued at $161,760. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 44,026 shares of company stock valued at $1,135,234. Corporate insiders own 18.86% of the company’s stock.

Several institutional investors have recently made changes to their positions in RVNC. Vanguard Group Inc. increased its position in shares of Revance Therapeutics by 5.1% during the 1st quarter. Vanguard Group Inc. now owns 868,118 shares of the biopharmaceutical company’s stock worth $18,056,000 after purchasing an additional 42,466 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Revance Therapeutics by 16.4% during the 1st quarter. Geode Capital Management LLC now owns 178,435 shares of the biopharmaceutical company’s stock worth $3,711,000 after purchasing an additional 25,075 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Revance Therapeutics by 4.4% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 92,490 shares of the biopharmaceutical company’s stock worth $1,924,000 after purchasing an additional 3,933 shares in the last quarter. Bank of America Corp DE increased its position in shares of Revance Therapeutics by 29.5% during the 1st quarter. Bank of America Corp DE now owns 7,247 shares of the biopharmaceutical company’s stock worth $151,000 after purchasing an additional 1,651 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. increased its position in shares of Revance Therapeutics by 14.8% during the 2nd quarter. Candriam Luxembourg S.C.A. now owns 140,000 shares of the biopharmaceutical company’s stock worth $3,696,000 after purchasing an additional 18,000 shares in the last quarter. Institutional investors and hedge funds own 88.70% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was first posted by Stock Observer and is owned by of Stock Observer. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this news story can be read at https://www.thestockobserver.com/2017/12/07/revance-therapeutics-rvnc-pt-raised-to-51-00.html.

About Revance Therapeutics

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply